title: Role of mitomycin C in reducing adhesion formation following endoscopic sinus surgery.
abstract: OBJECTIVE
  To study the role of mitomycin C in reducing adhesion formation following endoscopic sinus surgery.
  
  
  METHODS
  Prospective, randomized, controlled trial.
  
  
  METHODS
  Tertiary care referral centre.
  
  
  METHODS
  Thirty patients were selected suffering long-term problems with bilateral chronic rhinosinusitis, with no relief obtained from medical therapy. Patients requiring revision sinus surgery or having acute upper respiratory tract infection were excluded.
  
  
  METHODS
  Diagnostic nasal endoscopies and non-contrast computerized tomography of nose and paranasal sinuses were undertaken and, following confirmation of the diagnosis, functional endoscopic sinus surgery (FESS) was carried out bilaterally using the Messerklinger technique. On completion of the surgery, a cotton wick soaked in mitomycin C was placed in one or other side of the nose in the middle meatus. Follow up was for three months and patients were assessed for subjective and objective improvement in their symptoms.
  
  
  RESULTS
  Post-operatively, of the 11 (36.6 per cent) patients complaining of persistent nasal obstruction, nine had complaints limited to the control side only (p=0.005). Out of the nine (30 per cent) patients complaining of recurrent nasal discharge, eight had complaints on the control side and only one reported discharge from both sides (p=0.006).
  
  
  CONCLUSIONS
  Mitomycin C may be topically applied in post-operative FESS cases to reduce adhesion formation and hence the need for revision surgery.
authors.affiliation: Department of Otorhinolaryngology, Vardhaman Mahavir Medical College and Safdarjang Hospital, New Delhi, India. monicamanish2001@yahoo.co.nz
authors.forename: M
authors.initials: M
authors.lastname: Gupta
authors.forename: G
authors.initials: G
authors.lastname: Motwani
mesh_terms: D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D004724:Endoscopy / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D016685:Mitomycin / Q000627:therapeutic use*; D015508:Nasal Obstruction / Q000517:prevention & control; D010256:Paranasal Sinuses / Q000601:surgery; D011183:Postoperative Complications / Q000517:prevention & control*; D011446:Prospective Studies; D012852:Sinusitis / Q000601:surgery*; D000267:Tissue Adhesions / Q000517:prevention & control; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D016685:Mitomycin